Ernexa Therapeutics to Execute Reverse Stock Split to Avoid Nasdaq Delisting

summarizeSummary

Ernexa Therapeutics Inc. is preparing for a reverse stock split, with a ratio between 1-for-10 and 1-for-25, to regain compliance with Nasdaq's minimum bid price requirement and prevent delisting.

check_boxKey Events

• Reverse Stock Split Approved

  The Board of Directors and majority shareholders (51.63%) have approved a reverse stock split.

• Flexible Split Ratio

  The split ratio will be between 1-for-10 and 1-for-25, with the exact ratio to be determined by the Board.

• Purpose: Nasdaq Compliance

  The primary goal of the reverse split is to increase the per-share price to meet Nasdaq's $1.00 minimum bid price requirement and avoid delisting.

• No Further Shareholder Vote Required

  The action was approved by written consent of majority shareholders, eliminating the need for an additional shareholder meeting or vote.

auto_awesomeAnalysis

This preliminary information statement details Ernexa Therapeutics' plan to implement a reverse stock split, a direct response to the Nasdaq delisting notice received on March 20, 2026. While a necessary step to maintain its listing, reverse splits often signal underlying operational challenges and can lead to further stock price volatility and reduced liquidity. The board and majority shareholders have already approved this action, which will become effective no earlier than 20 days after the mailing of this statement. Investors should monitor the effectiveness of the split in maintaining Nasdaq compliance and the company's ability to address its fundamental business issues.